WellDoc raises $20 million from Merck, others
Summary
WellDoc secured a $20 million Series A from Merck Global Health Innovation Fund and Windham Venture Partners. The company develops BlueStar, a prescribable smartphone app for Type 2 diabetes management. The piece highlights WellDoc’s reimbursement model, existing insurer and employer relationships, and its broader partner network with companies such as Ford, AT&T, Alere, and RiteAid. It also notes that Merck’s involvement fits with its interest in digital health and related care models.
Funding
Amount
$20.0M
Total raised
Date
January 10, 2014
Announcement date
Investors
Windham Venture Partners, Merck Global Health Innovation Fund, Merck Global Health Innovation Fund, LLC, Rite Aid, AT&T CyberSecurity
Lead investors
Company
welldoc.com
Funded company
Classifications
industries
HealthTech
applications
Data Management
AskAI Classifications
Labels
Digital Health
Chronic Care Management
SaaS
Linked Companies
Welldoc
$10M to $25M